NCT05610319进行中（未招募）4 期
Treat & Extend Versus Fixed Dosing With Faricimab for Management of Diabetic Macular Edema: A Pragmatic, Multi-center, Open-label, Randomized, Controlled Trial
适应症
干预措施
相关药物
试验速览
- 阶段
- 4 期
- 状态
- 进行中（未招募）
- 入组人数
- 446
- 试验地点
- 46
- 主要终点
- Change in Best Corrected Visual Acuity
研究概览
简要总结
This study will assess a pragmatic, treat and extend regimen of faricimab against the standard of a fixed dosing regimen.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- Single (Outcomes Assessor)
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Age ≥ 18 years
- •Diagnosis of diabetes mellitus (type 1 or type 2).
- •Macular thickening secondary to DME (CI-DME) involving the center of the fovea on Optical Coherence Tomography - Central subfield thickness (CST) ≥ 325 μm on Spectralis at screening.***
- •Visual impairment due to DME, with best corrected visual acuity of 80 to 20 letters (Snellen VA 20/25 - 20/400).
- •Media clarity, pupillary dilation, and individual cooperation sufficient for adequate OCT and fundus photographs.
- •Hemoglobin A1c must be <10% within 2 months prior to 1st study treatment.
- •Provide signed informed consent.
排除标准
- •Active or history of ocular inflammation or suspected/active ocular infection in either eye.
- •High-risk proliferative diabetic retinopathy in the study eye.**
- •Tractional retinal detachment, preretinal fibrosis or visually significant epiretinal membrane involving the macula.
- •Uncontrolled glaucoma (intraocular pressure >30 with or without medications).
- •Any intravitreal, periocular or implant corticosteroids within 26 weeks (6 months) before day 1 or any use of Iluvien implants.
- •Treatment with Panretinal photocoagulation (PRP) within 12 weeks before day
- •Treatment with macular laser.
- •Any cataract surgery or any other intraocular surgery within 12 weeks before day
- •Macular edema in study eye due to a cause other than DME.
- •If clinical exam and/or OCT and/or wide-field fluorescein angiography (WF-FA) suggest that (a) macular edema is considered to be related to ocular surgery such as cataract extraction or (b) if primary cause for macular edema is vitreoretinal interface abnormalities (e.g. a taut posterior hyaloid or epiretinal membrane).
- •Any ocular condition is present such that visual acuity loss would not improve from resolution of macular edema in opinion of the investigator (e.g. foveal atrophy, pigment abnormalities, dense subfoveal hard exudates, nonretinal condition)
- •Any history of ocular conditions that might affect macular edema (e.g. vein occlusion, idiopathic or infectious or non-infectious uveitis, ocular inflammatory disease, neovascular glaucoma etc.)
- •Women of child-bearing potential who are lactating, pregnant, or intending to become pregnant within the next 100 weeks.
- •Current or anticipated incarceration.
- •Terminal illness with expected survival less than 100 weeks.
- •Known hypersensitivity to faricimab or any of the excipients in the faricimab injection.
- •Currently enrolled in a study that does not permit co-enrollment.
- •Unable to obtain informed consent due to language or other operational barriers.
- •Anticipated problems, in the judgment of the site investigator, maintaining compliance with the protocol, including attending study visits, completing assessments or procedures.
- •Prior enrollment in this trial.
- •Other reason to exclude the patient, as approved by the sponsor and site investigator.
- •Previous treatment with anti-VEGF and:
- •<12 weeks prior to day 1 (washout period).*or,
- •Diagnosis of DME is > 2 years of enrollment or,
- •Do not have a demonstrated response to anti-VEGF treatment based on clinical discretion.
研究组 & 干预措施
Control/Usual Care Arm
Other
Participants in the control arm will receive 6 milligrams (mg) faricimab intravitreal (IVT) injections monthly (28d +/-7 days), for 6 treatments. Afterwards, participants will continue to receive 6mg faricimab IVT every 8 weeks until week 100.
干预措施: Faricimab (Drug)
Treat and Extend
Experimental
Participants randomized to the T&E Arm will initially receive 6 milligrams (mg) faricimab intravitreal (IVT) injections monthly (28d +/-7 days), with treatment intervals increased/extended, reduced, or maintained based on CST assessments, until week 100.
干预措施: Faricimab (Drug)
结局指标
主要结局
Change in Best Corrected Visual Acuity
时间窗: Baseline to Week 100
Change in best corrected visual acuity (3.9 letter non-inferiority margin)
次要结局
- Decrease in Diabetic Retinopathy Severity Score(Baseline to Week 100)
- Dosing Interval(Week 100)
- Absence of Diabetic Macular Edema(Week 100)
- Presence of Safety Outcomes(Baseline to Week 100)
- Change in Letters of Vision(Baseline to Week 100)
- Absence of Intraretinal Fluid (IRF)(Week 100)
- Change in Central Subfield Thickness(Baseline to Week 100)
- Change in Vision Related Quality of Life(Baseline to Week 100)
研究者
研究点 (46)
Loading locations...
相似试验
已完成
3 期
A Study to Evaluate the Efficacy and Safety of Faricimab in Participants With Neovascular Age-Related Macular Degeneration (LUCERNE)Wet Macular DegenerationNCT03823300Hoffmann-La Roche658
已完成
3 期
A Study to Evaluate the Efficacy and Safety of Faricimab in Participants With Neovascular Age-Related Macular Degeneration (TENAYA)Wet Macular DegenerationNCT03823287Hoffmann-La Roche671
已完成
3 期
A Study to Evaluate the Efficacy and Safety of Faricimab (RO6867461) in Participants With Diabetic Macular EdemaDiabetic Macular EdemaNCT03622593Hoffmann-La Roche951
已完成
3 期
A Study to Evaluate the Efficacy and Safety of Faricimab (RO6867461) in Participants With Diabetic Macular Edema (YOSEMITE)Diabetic Macular EdemaNCT03622580Hoffmann-La Roche940
已完成
3 期
A Study of Two Fabrazyme (Agalsidase Beta) Dosing Regimens in Treatment-naïve, Male Pediatric Patients Without Severe SymptomsFabry DiseaseNCT00701415Genzyme, a Sanofi Company31